Status:
WITHDRAWN
Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation
Lead Sponsor:
The University of Texas Health Science Center, Houston
Conditions:
Suicidal Ideation
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Suicide is a major crisis worldwide with rates projected to continue to increase. There is currently a dearth of novel pharmacologic treatment options for suicide available on the market. The endocann...
Eligibility Criteria
Inclusion
- Able to provide written informed consent
- Current suicidal ideation
- Columbia Suicide Severity Rating Scale (CSSRS) score of ≥ 4 and Scale for Suicide Ideation (SSI) first 5 items, score of ≥4
- Current major depressive episode as evidenced by MADRS score ≥ 20
Exclusion
- Current diagnosis of a Diagnostic and Statistical Manual V (DSM-V) psychotic disorder, psychotic symptoms, or personality disorder.
- Recent (\<72 hrs) use of illicit substances
- Comorbid substance use disorder diagnosis
- Urine drug screen (UDS) positive for tetrahydrocannabinol (THC)
- Pregnant or nursing women
- Unstable medical condition
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04807829
Start Date
April 1 2021
End Date
April 1 2022
Last Update
September 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Harris County Psychiatric Center (HCPC)
Houston, Texas, United States, 77021